1. All the following are TRUE about breast cancer disparities related to triple-negative breast cancer (TNBC) EXCEPT:

2. All of the following contribute to the multifaceted intersection between biological and nonbiological factors in TNBC disparities EXCEPT:

3. The 2020 American Society of Clinical Oncology (ASCO) study by Ubbaonu et al showed that non-concordance with National Comprehensive Cancer Network (NCCN) treatment guidelines was associated with which of the following?

4. Patient GP is a 46-year-old Ashkenazi Jewish woman recently diagnosed with breast cancer with metastasis to the lungs. Her biomarker profile shows that her breast cancer is estrogen/progesterone receptor negative, human epidermal growth factor receptor 2 (HER2) with immunohistochemistry 1+, and breast cancer gene (BRCA)1/2 positive. Based on her presentation, GP is determined to have metastatic HER2-low TNBC. Using her biomarker expression as a guide for treatment selection, which option is most appropriate and guideline concordant for GP?

5. If GP's biomarker profile showed her to be BRCA1/2 negative, which treatment option would be most appropriate and guideline concordant?

6. At Cancer Committee, your quality improvement team presents data indicating significant disparities between Black women and White women with breast cancer in your community. Which of the following are evidence-based strategies to address this disparity in your patient population?

7. Patient MJ, a 53-year-old Black female, has recurrent, advanced-stage TNBC. The tumor tests positive for PD-L1. She also has uncontrolled diabetes and is clinically obese. She has a high deductible health insurance plan and has expressed nervousness about traveling for treatment since she has no paid leave, is paid by the hour, and lives more than an hour from the cancer center. She is divorced and has 4 young children, including one with special needs. All of the following are factors that can contribute to breast cancer disparities and less favorable treatment outcomes in MJ EXCEPT:

Evaluation Questions

8. How confident are you in your treatment choices for GP in question #4 above?

« Return to Activity